Peter Olagunju is the Chief Technology Officer for TCR2. Previous to TCR2, Peter served as the SVP of Technical Operations at FerGene (a Blackstone Life Sciences backed start-up) where he worked on the commercialization of a gene therapy of bladder cancer. Previous to FerGene Peter served as the Vice President of Patient Operations with bluebird bio. In this role, Peter had responsibility for the personalized manufacturing & Centers of Excellence (COE) interfaces including the collection of patient cells, manufacture of drug product, and operational execution of patient treatments. Peter’s team de...read more